[Form 4] Stoke Therapeutics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Edward M. Kaye, MD, a director of Stoke Therapeutics (STOK), sold common stock in three transactions executed under a Rule 10b5-1 trading plan adopted December 30, 2024. The transactions show sales of 1,029 shares, 14,860 shares and 45,996 shares at weighted-average prices of $20.00 (single sale) and approximately $20.1386 and $20.1291 respectively. Following these reported sales the filing shows beneficial ownership of 91,585 shares, down from 152,441 shares after the first reported sale, reflecting a reduction of 60,856 shares in reported beneficial holdings. The filing discloses that the weighted-average sale prices ranged from $20.00 to $20.40 and that the reporting person will provide detailed per-price sale information on request.

Positive

• Sales executed under a Rule 10b5-1 plan, indicating pre-established trading instructions and stronger compliance posture
• Weighted-average prices disclosed and an explicit offer to provide per-price sale details, enhancing transparency

Negative

• Material reduction in beneficial ownership: reported holdings decreased from 152,441 shares to 91,585 shares (a reduction of 60,856 shares)
• Concentration of sales within a narrow price range (~$20.00 to $20.40), which may be noted by investors tracking insider liquidity

Insights

Securities Analyst

TL;DR: Routine insider selling under a 10b5-1 plan, disclosed with weighted-average prices and remaining holdings.

The transactions appear to be systematic sales executed under a pre-established Rule 10b5-1 plan, which typically reduces timing risk and insider-trading concerns. The filing shows three sales totaling 61,885 shares reported across the lines and a reported decrease in beneficial ownership to 91,585 shares. Disclosed weighted-average prices fall in a narrow $20.00 to $20.40 range, and the reporting person offers to provide per-price sale details on request, which supports transparency. This disclosure is standard for director sales and provides clear data for monitoring insider ownership trends.

Corporate Governance Expert

TL;DR: Director sales were pre-planned and properly disclosed; documentation supports compliance with Rule 10b5-1.

The form indicates the trades were executed pursuant to a Rule 10b5-1 plan adopted on December 30, 2024, and the filer checked the box confirming that status, which strengthens the affirmative defense against claims of opportunistic trading. The form lists the reporting person as a director and provides weighted-average prices and a commitment to supply detailed execution-level data upon request. From a governance perspective, the filing meets common disclosure expectations for officer/director sales but does reflect a material reduction in reported beneficial ownership that stakeholders may note.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kaye Edward M. MD

(Last) (First) (Middle)

C/O STOKE THERAPEUTICS, INC.

45 WIGGINS AVENUE

(Street)

BEDFORD MA 01730

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Stoke Therapeutics, Inc. [ STOK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/29/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/29/2025		S(1)		1,029	D	$20	152,441	D
Common Stock	09/02/2025		S(1)		14,860	D	$20.1386(2)	137,581	D
Common Stock	09/03/2025		S(1)		45,996	D	$20.1291(3)	91,585	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2024.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.40, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 3 of this Form 4.

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.40, inclusive.

	/s/ Jonathan Allan, Attorney-in-Fact	09/03/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

Who is the reporting person in this Form 4 for STOK?

The reporting person is Edward M. Kaye, MD, identified as a director of Stoke Therapeutics (STOK).

Were the sales executed under a pre-established trading plan?

Yes. The filing indicates the transactions were executed pursuant to a Rule 10b5-1 trading plan adopted December 30, 2024.

How many shares were sold and what are the weighted-average prices?

The Form 4 reports sales of 1,029, 14,860, and 45,996 shares at weighted-average prices of approximately $20.00, $20.1386, and $20.1291, respectively; overall sales prices ranged from $20.00 to $20.40.

What is the reporting person's beneficial ownership after these transactions?

Following the reported transactions the filing shows beneficial ownership of 91,585 shares.

Does the filing provide execution-level price details?

The filing states the reported prices are weighted averages and offers to provide full information about the number of shares sold at each separate price upon request.